A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) - PubMed (original) (raw)

Clinical Trial

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

Teri N Kreisl et al. J Neurooncol. 2009 Mar.

Abstract

Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.

PubMed Disclaimer

Similar articles

• Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
  de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. de Groot JF, et al. J Neurooncol. 2008 Oct;90(1):89-97. doi: 10.1007/s11060-008-9637-y. Epub 2008 Jun 26. J Neurooncol. 2008. PMID: 18581057 Free PMC article. Clinical Trial.
• Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
  Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Chheda MG, et al. J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2. Epub 2014 Dec 13. J Neurooncol. 2015. PMID: 25503302 Free PMC article. Clinical Trial.
• Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
  Custodio A, Calles A, Pérez-Segura P. Custodio A, et al. Clin Transl Oncol. 2010 Apr;12(4):310-4. doi: 10.1007/s12094-010-0510-z. Clin Transl Oncol. 2010. PMID: 20462843
• Emerging treatment combinations: integrating therapy into clinical practice.
  Wong ST. Wong ST. Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S9-S14. doi: 10.2146/ajhp090439. Am J Health Syst Pharm. 2009. PMID: 19923318 Review.
• Incorporating molecular tools into early-stage clinical trials.
  Weil RJ. Weil RJ. PLoS Med. 2008 Jan 22;5(1):e21. doi: 10.1371/journal.pmed.0050021. PLoS Med. 2008. PMID: 18215108 Free PMC article. Review.

Cited by

• EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry.
  Cornez I, Joel M, Taskén K, Langmoen IA, Glover JC, Berge T. Cornez I, et al. J Neurooncol. 2013 Mar;112(1):49-57. doi: 10.1007/s11060-012-1035-9. Epub 2013 Jan 9. J Neurooncol. 2013. PMID: 23299461
• Novel Treatment Strategies for Glioblastoma.
  Stylli SS. Stylli SS. Cancers (Basel). 2020 Oct 8;12(10):2883. doi: 10.3390/cancers12102883. Cancers (Basel). 2020. PMID: 33049911 Free PMC article.
• Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.
  Krakstad C, Chekenya M. Krakstad C, et al. Mol Cancer. 2010 Jun 1;9:135. doi: 10.1186/1476-4598-9-135. Mol Cancer. 2010. PMID: 20515495 Free PMC article. Review.
• mTOR signaling in glioblastoma: lessons learned from bench to bedside.
  Akhavan D, Cloughesy TF, Mischel PS. Akhavan D, et al. Neuro Oncol. 2010 Aug;12(8):882-9. doi: 10.1093/neuonc/noq052. Epub 2010 May 14. Neuro Oncol. 2010. PMID: 20472883 Free PMC article. Review.
• Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
  Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Reardon DA, et al. J Neurooncol. 2010 Jan;96(2):219-30. doi: 10.1007/s11060-009-9950-0. Epub 2009 Jun 28. J Neurooncol. 2010. PMID: 19562254 Free PMC article. Clinical Trial.

References

1. 1. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 - PubMed
2. 1. PLoS Med. 2008 Jan 22;5(1):e8 - PubMed
3. 1. J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 - PubMed
4. 1. Neurology. 2006 Jul 11;67(1):156-8 - PubMed
5. 1. Invest New Drugs. 2005 Aug;23(4):357-61 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal